IND-enabling studies

Advertent Biotherapeutics, Inc. is a privately held biotechnology company advancing new therapies to help people maintain strength and mobility when muscle is damaged by genetic diseases, injury, or aging. Founded in 2019 as a spin-out from Michigan State University, it combines expertise in growth factor biology, muscle pathology, and drug development to build first-in-class biologics that protect muscle quality over the long term.

biologics discoverydrug developmentpreclinical developmentstructure-guided protein engineering

AliquantumRx is a near-clinical infectious-disease company focused on eliminating liver-stage malaria relapse. It is developing Cethromycin HCl through its CALM (Cethromycin Against Liver-Stage Malaria) program, a short-course, G6PD testing-independent oral therapy designed to eliminate dormant liver-stage malaria and prevent relapse. The company is supported by over $6M in non-dilutive funding for IND-enabling studies and early clinical development and is pursuing human proof-of-concept and potential Priority Review Voucher eligibility.

clinical developmentdrug development

CMTx Biotech, Inc. is a Stony Brook, NY company developing medical countermeasures against high priority CBRN threats. It pursues drug rescue and repositioning, including new therapeutic uses and formulations of clinical stage drug candidates and of drugs already approved for human use. Its science focuses on host-directed therapeutics (HDTs) targeting hyper-inflammatory and dysregulated immune responses to infection, insult, or injury. Lead candidate incyclinide has completed IND-enabling studies; CMTx R2 is an STS protein inhibitor advanced for host-di

drug developmentdrug repurposinghost-directed therapeuticsmanufacturingtechnology commercialization and licensing

Coeurative, Inc. is developing a pharmaceutical management strategy for Coronary Artery Disease and its main symptom complex, Angina Pectoris. The company is harnessing a cellular response to a deficiency in blood and oxygen to open a coronary artery more effectively and selectively than currently available vasodilators, with a focus on patients with INOCA and refractory angina pectoris. Its lead compound CR-0305 uses a proprietary dual-mechanism approach, with IND-enabling studies underway and Phase 1 trials planned for 2028.

pharmaceutical development

Cognitive Synergy Corporation is a biotechnology company developing novel small-molecule therapies for Alzheimer's disease and related neurodegenerative disorders. Its lead candidate is designed to restore synaptic health while reducing amyloid and tau pathology, aiming to be a disease-modifying treatment. The company integrates translational biomarkers, pharmacology, and behavioral outcomes and is progressing its small molecule through IND-enabling studies toward early clinical trials.

pharmacologypreclinical researchsmall molecule drug discoverytranslational biomarkers

Irazu Oncology, LLC is a clinical-stage biotech founded in 2022 developing off-the-shelf cancer immunotherapies built on a proprietary bacterial outer membrane vesicle (OMV) platform. The platform creates customized, self-adjuvanted mono/multivalent therapeutic vaccines carrying tumor antigens and immune-activating signals. Its lead program, IRZ-03, is a first-in-class multimodal OMV immunotherapy targeting CEA, MUC1, and PD-L1 for checkpoint inhibitor-refractory solid tumors.

bacterial outer membrane vesicle (OMV) platformscalable bacterial fermentationvaccine development